{
    "clinical_study": {
        "@rank": "149885", 
        "brief_summary": {
            "textblock": "To determine response rate, median time to tumor progression, qualitative and quantitative\n      toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated\n      Kaposi's sarcoma (KS) administered a 3-hour infusion of paclitaxel every 14 days. To\n      evaluate the clinical benefit of paclitaxel in this patient population by evaluating\n      self-reported responses to the Symptom Distress Scale and by documenting and evaluating any\n      changes in their lymphedema, pain and disfiguring facial lesions."
        }, 
        "brief_title": "Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are treated with paclitaxel intravenously every 2 weeks up to 10 courses. Patients\n      who achieve a complete response receive 2 additional courses those who achieve partial\n      response or stabilization, continue therapy until progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Microscopically confirmed diagnosis of KS associated with HIV for which systematic\n             therapy is medically indicated by the presence of at least one of the following:\n\n        A. >= 25 mucocutaneous (mouth or skin) lesions. B. Symptomatic visceral involvement. C.\n        Symptomatic lymphedema (pain).\n\n          -  Minimum of 5 clearly measurably cutaneous lesions by physical exam or measurable\n             disease by X-ray, CT or MRI.\n\n          -  Failed at least one systemic chemotherapy regimen.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions and symptoms are excluded:\n\n          -  Less than 2 weeks since major surgery.\n\n          -  Serious uncontrolled infection. NOTE:\n\n          -  Must be ruled out by thorough work-up in patients with unexplained fevers, night\n             sweats, or involuntary weight loss of more than 10% normal weight.\n\n          -  Leukopenia.\n\n          -  Thrombocytopenia.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of angina or myocardial infarction within the past 6 months.\n\n          -  Second degree or third degree atrioventricular block without a pacemaker.\n\n          -  Congestive heart failure (poorly controlled).\n\n          -  History of prior malignancy except:\n\n        Completely excised in situ, carcinoma of the cervix or nonmelanomatous skin cancer.\n\n        Curatively treated other malignancy with no evidence of disease for at least 5 years.\n\n        Prior Medication:\n\n        Excluded:\n\n        Prior taxane therapy.\n\n        Required:\n\n          -  At least one systemic chemotherapy regimen that failed to maintain significant\n             benefit. NOTE:\n\n          -  Intralesional chemotherapy regimens are not considered as prior chemotherapy.\n\n          -  At least 2 weeks since last dose of prior systemic chemotherapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002189", 
            "org_study_id": "273A", 
            "secondary_id": "IX-110-081"
        }, 
        "intervention": {
            "intervention_name": "Paclitaxel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antineoplastic Agents", 
                "Paclitaxel", 
                "Antineoplastic Agents, Phytogenic"
            ]
        }, 
        "keyword": [
            "Sarcoma, Kaposi", 
            "Acquired Immunodeficiency Syndrome", 
            "Paclitaxel", 
            "Treatment Outcome", 
            "Antineoplastic Agents, Phytogenic"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts Gen Hosp / AIDS Oncology Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002189"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baker Norton Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1998"
    }, 
    "geocoordinates": {
        "Massachusetts Gen Hosp / AIDS Oncology Research": "42.358 -71.06"
    }
}